News
Arjuna Natural has been granted a new European patent for its applied technology of improving the bioavailability of curcumin in its BCM-95 (Curcugreen) formulation.
The patented formulation provides biologically active curcumin with essential oil of turmeric.
The 100% natural formulation is said to be extensively backed by over 55 published studies worldwide and several ongoing studies for its therapeutic activity on multiple health indications, making it unparalleled in the segment.
The formulation is already protected by 49 patents (14 in the US, two in Japan and 33 in European countries) for composition and manufacturing processes of curcumin extract.
“The composition of BCM-95 (Curcugreen) contains only turmeric based components and no synthetic or non-turmeric ingredients,” said Benny Antony, Joint Managing Director for Arjuna. “This composition of turmeric delivers free curcumin into blood and is retained in the body for longer duration.”
Arjuna says that this patent in effect helps to address much confusion in the market regarding curcumin absorption and oral bioavailability. The main problem of curcumin, the company claims, is that it is not absorbed nor retained well in the blood streams - yet the market has subsequently been flooded with curcumin products laden with synthetic additives in attempts to overcome the issue of bioavailability. Also, Arjuna claims, it is observed that many brands are toll manufactured at production centers not complying to cGMP standards.
“Any supplement you put into your body should be both safe and effective,” said Antony. “Arjuna’s BCM-95 (Curcugreen) is wholly manufactured in its own facility under a fully automated cGMP complied continuous extraction plant—using only solar power. This has enabled Arjuna to triple its manufacturing capacity in Coimbatore, India to meet the growing demand for their brand of curcumin in the coming years.”
According to the company, the success of BCM-95 (Curcugreen) has enabled Arjuna to rev up its marketing activities and cement its foothold in the European market as well as in the USA.
“With the mobilization of our dedicated sales force we hope to increase our market reach significantly in the coming years,” said P.J Kunjachan, Chairman & Managing Director.
23 Dec 2025
From trade tariffs to heavy metals in protein, we look back at some of the industry’s highlights of 2025 and round up our most-read stories of the year.
Read more
19 Dec 2025
Non-profit organisation the Food Foundation has launched a campaign, “Bang in Some Beans”, designed to increase UK consumers’ legume consumption.
Read more
12 Dec 2025
Europe’s $40.7 billion supplements market is growing fast, fuelled by demand for products that support healthy ageing, mental wellbeing, and preventive health, say experts.
Read more
11 Dec 2025
Whole Foods Market has released its top 2026 trends, predicting that a fibre frenzy will take place next year as health-conscious consumers seek out nutritious, filling options.
Read more
9 Dec 2025
With the launch of Novak Djokovic’s sorghum-based brand, the grain’s popularity in the better-for-you snacking sphere is on the rise, thanks to its nutritional and sensory properties.
Read more
8 Dec 2025
Plant-based dairy is a maturing market that still faces significant hurdles around taste, functionality, nutrition, and price, but industry is innovating fast, according to experts speaking at Fi Europe.
Read more
3 Dec 2025
Food industry stakeholders celebrated as the winners of the Fi Europe Innovation Awards were announced at a ceremony in Paris.
Read more
28 Nov 2025
Entries for the Vitafoods Europe Innovation Awards 2026 are now open! Game-changing companies have until 27 February to submit their entry across eight categories for the chance to win big.
Read more
25 Nov 2025
Cinnamon may be a top functional ingredient, but it needs stronger protocols to ensure it meets EU food safety laws and quality standards, say researchers.
Read more
24 Nov 2025
OXO’s entry into bone broth has turned the spotlight on this small but high-performance category – and there is still scope for growth, especially in the area of GLP-1 support.
Read more